Wall Street brokerages expect FibroGen, Inc (NASDAQ:FGEN) to post $34.80 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for FibroGen’s earnings, with estimates ranging from $29.50 million to $42.03 million. FibroGen posted sales of $89.28 million in the same quarter last year, which would indicate a negative year over year growth rate of 61%. The company is expected to report its next earnings report on Monday, August 7th.

According to Zacks, analysts expect that FibroGen will report full year sales of $34.80 million for the current year, with estimates ranging from $138.00 million to $152.98 million. For the next financial year, analysts expect that the firm will report sales of $236.07 million per share, with estimates ranging from $214.00 million to $266.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover FibroGen.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.11. FibroGen had a negative net margin of 37.60% and a negative return on equity of 36.41%. The company had revenue of $26.89 million during the quarter, compared to analysts’ expectations of $26.02 million.

FGEN has been the topic of a number of analyst reports. Jefferies Group LLC initiated coverage on shares of FibroGen in a research note on Monday, July 10th. They set a “buy” rating and a $50.00 price objective on the stock. Citigroup Inc. reiterated a “buy” rating and set a $48.00 price objective on shares of FibroGen in a research note on Monday, June 26th. Stifel Nicolaus reiterated a “buy” rating and set a $38.00 price objective (up previously from $32.00) on shares of FibroGen in a research note on Thursday, June 22nd. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Goldman Sachs Group, Inc. (The) lowered shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective on the stock. in a research note on Friday, July 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $40.57.

FibroGen (FGEN) opened at 33.40 on Tuesday. The firm’s market cap is $2.34 billion. FibroGen has a 12-month low of $15.60 and a 12-month high of $35.85. The firm’s 50-day moving average is $32.84 and its 200 day moving average is $27.51.

In other news, Director Toshinari Tamura sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $28.89, for a total transaction of $866,700.00. Following the completion of the sale, the director now owns 60,000 shares of the company’s stock, valued at $1,733,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Thomas B. Neff sold 38,636 shares of the firm’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $27.70, for a total transaction of $1,070,217.20. Following the sale, the chief executive officer now directly owns 3,345,941 shares of the company’s stock, valued at approximately $92,682,565.70. The disclosure for this sale can be found here. Insiders have sold 409,974 shares of company stock valued at $12,647,338 in the last three months. Corporate insiders own 14.90% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in FibroGen by 8.4% in the first quarter. Vanguard Group Inc. now owns 5,047,018 shares of the biopharmaceutical company’s stock worth $124,409,000 after buying an additional 392,778 shares during the last quarter. BlackRock Inc. increased its stake in FibroGen by 29,724.1% in the first quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock worth $109,811,000 after buying an additional 4,439,882 shares during the last quarter. FMR LLC increased its stake in FibroGen by 10.5% in the first quarter. FMR LLC now owns 1,694,574 shares of the biopharmaceutical company’s stock worth $41,771,000 after buying an additional 161,143 shares during the last quarter. State Street Corp increased its stake in FibroGen by 11.1% in the first quarter. State Street Corp now owns 1,514,465 shares of the biopharmaceutical company’s stock worth $37,336,000 after buying an additional 150,807 shares during the last quarter. Finally, Janus Capital Management LLC increased its stake in FibroGen by 1.1% in the first quarter. Janus Capital Management LLC now owns 1,363,657 shares of the biopharmaceutical company’s stock worth $33,613,000 after buying an additional 14,882 shares during the last quarter. 43.45% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/08/fibrogen-inc-nasdaqfgen-expected-to-post-quarterly-sales-of-34-80-million.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get a free copy of the Zacks research report on FibroGen (FGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.